|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.3700 - 0.4090|
|52 Week Range||0.3000 - 1.0400|
|Beta (3Y Monthly)||-2.27|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
United Cannabis Corporation (CNAB) (the “Company” or “United Cannabis”) surpassed a significant hurdle in its pending patent infringement case against Pure Hemp Collective when United States District Judge William Martinez held that “[d]espite the ambiguities, the Court is convinced under the current state of the case law that the challenged claims of the 911 Patent are not directed at unpatentable subject matter . The Court also dispensed with Pure Hemp’s contention that Claim 31 of the 911 Patent, a dependent claim that adds a medium chain triglyceride (MCT) to the claimed formulations, was invalid under 35 U.S.C. § 112. Noting that United Cannabis had previously corrected a multiple dependency problem via disclaimer, Judge Martinez held “[i]n short, there is neither a good reason nor a statutory basis to declare Claim 31 invalid, even though it previously depended on multiple dependent claims.
United Cannabis Corporation (CNAB) (the “Company” or “United Cannabis”) today announced that it has entered into a Partnership with John Easterling, environmentalist and founder of the multi-million dollar Amazon Herb Company, to create and produce formulations that combine the health benefits of cannabinoids with botanicals from the Amazonian Rainforest.
DENVER, CO / ACCESSWIRE / February 12, 2019 / United Cannabis Corporation (CNAB) (the ''Company'' or ''United Cannabis'') today announced that it has entered into a Joint Venture with Blue Water Green Bridge, LLC (Blue Water) a South Carolina company, to establish an industrial hemp processing plant. The new venture is named Magnolia Botanicals LLC, (''Magnolia''). Initially, Magnolia will provide industrial hemp extraction services for South Carolina farmers working under the 2018 Federal Farm Bill and the South Carolina Department of Agriculture's Industrial Hemp Pilot Program.
As we've seen over the past couple of months, several countries, including the United States, passed positive legislation in favor of the legalization of cannabis. As we continue to move through this new year, the hopes are that the cannabis industry will be able to see even more gains in the future. Biome Grow Inc (CSE:BIO) (BIOIF) (6OTA.F), Pyxus International Inc (PYX), United Cannabis Corporation (CNAB), and Cannabis Science Inc (OTC PINK: CBIS) are four cannabis companies determined to champion products and services designed with the consumer in mind.
Uptick Newswire Stock Day Podcast welcomed United Cannabis Corporation (CNAB), a biotechnology company dedicated to the development of phyto-therapeutic based products supported by patented technologies for the pharmaceutical, medical, and industrial markets. President and CEO, Earnie Blackmon, joined Stock Day host Everett Jolly to discuss the Company’s recent developments and their expectations for 2019.
DENVER, CO / ACCESSWIRE / January 15, 2019 / United Cannabis Corporation (CNAB) (the "Company" or "United Cannabis") today announced that it has launched an industrial hemp testing facility in Golden, Colorado. The Company will provide independent testing for processors and manufacturers working under the 2018 Federal Farm Bill and Colorado's Department of Agriculture's Industrial Hemp Program.
DENVER, CO / ACCESSWIRE / December 13, 2018 / United Cannabis Corporation (CNAB) (the "Company" or "United Cannabis") today provided an update on its operations. The Company experienced a 60-day delay in the delivery of industrial hemp processing equipment to its facility in Mead, Colorado, causing a delay in the scheduled expansion of its capacity at that facility as well as related revenue. The academic laboratory of Dr. Brent Reynolds, cofounder of Prana Therapeutics, Inc., the Company's 95% owned subsidiary, has been issued a Schedule 1 drug license from the DEA.
Revenues for the third quarter 2018 are $2 million, and approximately $4.2 for the year to date. The current harvest season has alleviated the seasonal shortage and, thus, Management believes the Company is still on track to report a minimum of $10 million in revenue for 2018. The third quarter 2018 revenues amount has not be subjected to an unaudited review by the Company's auditors, and may be subject to change upon the completions of such unaudited review.
DENVER, CO / ACCESSWIRE / September 25, 2018 / United Cannabis Corporation (CNAB) (the "Company" or "United Cannabis") today announced that its Joint Venture (the "Joint Venture" or "UCANN/CRD"), which is 50% owned with Jamaica-based Cannabis Research & Development ("CRD"), has received conditional approval of its license to cultivate, process, transport and conduct research on cannabis within Jamaica.
DENVER, CO / ACCESSWIRE / August 1, 2018 / United Cannabis Corporation (CNAB) (the "Company" or "United Cannabis") today announced that it has initiated clinical trials on its Prana Bio Nutrient Medicinals P1 Capsules for the treatment of chronic pain at Jamaica's University of the West Indies. The study, titled, "An Open Label, Phase 1, 2-Way crossover study evaluating the pharmacokinetics of Prana P1 THC activated capsules," is be conducted in conjunction with Cannabinoid Research & Development ("CRD"), the Company's Jamaican subsidiary, at the Centre For Cannabis Research at the University's Mona Campus.
Earnest Blackmon, United Cannabis' Chief Executive Officer, commented, "The pilot run of our industrial hemp facility was very successful, resulting in a breakout second quarter. The Company has long advocated the application of cannabinoids for medical applications and is building a platform for designing targeted therapies to increase the quality of life for patients around the world. The Company's products are patent protected, first in class medicines with applications to a global market.
Earnest Blackmon, United Cannabis' Chief Executive Officer, commented on the approval: "South Africa is one of many markets where medical marijuana is viewed favorably, and we look forward to establishing a strong presence there, and making our Prana products available to qualified patients across the country.